Wen-Shen-Tong-Luo-Zhi-Tong Decoction alleviates bone loss in aged mice by suppressing LONP1-mediated macrophage senescence

Qinfeng Zhou, Kaixuan Wang, Cong Wang, X.n Sun, Lining Wang, Jie Sun, Yalan Pan, Muzhe Li, Zitong Zhao, Shenkang Zhou, Qing Wang, Yafeng Zhang, Yong Ma, Yang GuoPharmaceutical 2025 · DOI

TL;DR

This study reveals that a traditional Chinese herbal formula, Wen-Shen-Tong-Luo-Zhi-Tong Decoction (WSTLZTD), can combat age-related bone loss (osteoporosis) by targeting senescent macrophages. WSTLZTD appears to work by modulating the LONP1 protein in these macrophages, which in turn suppresses the cGAS/STING pathway in bone-forming cells (BMSCs), ultimately promoting bone health.

What Problem Does This Paper Address?

As we age, our bones become more fragile, leading to osteoporosis. This decline is linked to changes in our immune system, specifically a phenomenon called "immunosenescence," where immune cells like macrophages become senescent (aged and dysfunctional). These senescent macrophages in the bone marrow disrupt the normal balance of bone formation and resorption, contributing to bone loss. While traditional Chinese medicine offers potential treatments, the precise molecular mechanisms by which these remedies work, especially in naturally aged individuals, are often unclear. This paper aims to unravel how WSTLZTD, a clinically validated herbal formula for osteoporosis, exerts its protective effects by focusing on the role of macrophage senescence in age-related bone loss.

Methods

The researchers employed a multi-pronged approach:

  • In Vivo Studies: Aged mice were treated with varying doses of WSTLZTD. Bone health was assessed using micro-computed tomography (micro-CT) for structural analysis, and histological staining (H&E, TRAP) to examine bone tissue and cell activity. Macrophage senescence was evaluated using markers like β-galactosidase staining and specific protein expression (p16, p21) via immunofluorescence.
  • In Vitro Studies: Bone marrow-derived macrophages (BMDMs) and bone marrow mesenchymal stem cells (BMSCs) were cultured. Conditioned media from senescent macrophages were used to study their impact on BMSC osteogenesis. Techniques included ALP and Alizarin Red S staining for mineralization, ROS assays for oxidative stress, and JC-1 staining for mitochondrial membrane potential.
  • Molecular Mechanisms: Western blotting and immunohistochemistry were used to analyze the expression levels of key proteins, including LONP1, cGAS, and STING, in both bone tissue and cultured cells.
  • Network Pharmacology and Molecular Docking: To identify potential molecular targets, network pharmacology was used to analyze drug-disease interactions. Molecular docking was then employed to predict the binding affinity of WSTLZTD's active compounds with the identified target, LONP1.
  • Inhibitor Studies: A specific LONP1 inhibitor (LONP1-IN-2) was used to confirm the role of LONP1 in WSTLZTD's mechanism of action.

Datasets

The study utilized data from experiments performed on C57BL/6J mice of different ages. No new public datasets were introduced or used for training/evaluation in the context of machine learning models.

Key Insights and Ideas

  • WSTLZTD Targets Macrophage Senescence: The study strongly suggests that WSTLZTD directly combats the aging of macrophages in the bone marrow, a key factor in age-related osteoporosis.
  • LONP1 as a Central Player: The research points to LONP1, a mitochondrial protease, as a crucial mediator. WSTLZTD appears to upregulate LONP1 in senescent macrophages, potentially reversing their detrimental effects.
  • The cGAS/STING Pathway Connection: A significant finding is the link between WSTLZTD's effect on macrophages and the cGAS/STING pathway in BMSCs. WSTLZTD's action on macrophages seems to suppress this pathway in BMSCs, which is beneficial for bone formation.
  • Herbal Medicine's Molecular Precision: This work demonstrates how a complex herbal formula can exert targeted effects at the molecular level, influencing specific protein expressions and signaling pathways.
  • Synergistic Action: The findings suggest a cascade: WSTLZTD -> LONP1 upregulation in macrophages -> cGAS/STING suppression in BMSCs -> enhanced BMSC osteogenesis -> bone protection.

Key Results

  • WSTLZTD treatment in aged mice dose-dependently improved bone microstructure, increased bone mineral density, and restored bone formation markers (OCN) while reducing osteoclast activity (TRAP).
  • WSTLZTD significantly reduced senescence markers (p16, p21, β-Gal) in macrophages from both bone tissue and cultured BMDMs.
  • Conditioned media from WSTLZTD-treated senescent macrophages enhanced BMSC osteogenic differentiation, reduced ROS, and restored mitochondrial membrane potential in BMSCs.
  • Network pharmacology identified LONP1 as a key target, and molecular docking showed favorable binding affinities between several WSTLZTD compounds and LONP1.
  • WSTLZTD upregulated LONP1 and downregulated cGAS/STING in bone tissue and BMDMs.
  • Inhibition of LONP1 with LONP1-IN-2 reversed the anti-senescence effects of WSTLZTD on macrophages and its pro-osteogenic effects on BMSCs, confirming LONP1's critical role.

Limitations and Future Work

The authors acknowledge several limitations:

  • Clinical Evidence: While WSTLZTD has clinical use, large-scale, evidence-based studies specifically for SOP are limited.
  • Pharmacokinetics/Interactions: The bioavailability, pharmacokinetics, and potential herb-drug interactions of WSTLZTD require further investigation.
  • Direct Compound-Target Validation: Direct experimental validation of the binding and regulatory abilities of WSTLZTD's specific compounds with LONP1 needs more detailed studies (e.g., SPR experiments).
  • Molecular Mechanism Validation: Stricter experimental validation of molecular mechanisms, including genetic studies like LONP1 siRNA in vitro and potentially LONP1 knockout models (e.g., conditional knockout in BMDMs), is recommended.

Future work could focus on these areas to further solidify the therapeutic potential of WSTLZTD.

Summary updated

Abstract

WSTLZTD potentially modulate macrophage senescence via LONP1, which subsequently suppresses the activation of the cGAS/STING pathway in BMSCs, ultimately promoting their osteogenic differentiation and ameliorating osteoporosis.
BibTeX
@inproceedings{zhou2025wen,
  author = {Qinfeng Zhou and Kaixuan Wang and Cong Wang and X.N Sun and Lining Wang and Jie Sun and Yalan Pan and Muzhe Li and Zitong Zhao and Shenkang Zhou and Qing Wang and Yafeng Zhang and Yong Ma and Yang Guo},
  title = {{Wen-Shen-Tong-Luo-Zhi-Tong Decoction alleviates bone loss in aged mice by suppressing LONP1-mediated macrophage senescence}},
  booktitle = {Pharmaceutical},
  year = {2025},
  doi = {10.1080/13880209.2025.2537125},
}
Figure